RESUMO
OBJECTIVES: Our objective was to evaluate the pharmacokinetics of nelfinavir (NFV) (625 mg tablets) 1250 mg twice daily during pregnancy and postpartum. METHODS: The participants were HIV-1-infected pregnant women enrolled in P1026s and receiving NFV (625 mg tablets) 1250 mg twice daily as part of routine clinical care. Intensive steady-state 12-h NFV pharmacokinetic profiles were performed during pregnancy and postpartum. The target NFV area under the plasma concentration-time curve (AUC(0-12)) was >or=10th percentile NFV AUC(0-12) in non-pregnant historical controls (18.5 microg h/mL). RESULTS: Of 27 patients receiving NFV, pharmacokinetic data were available for four (second trimester), 27 (third trimester) and 22 (postpartum) patients. The NFV maximum concentration (C(max)), 12-h post-dose concentration (C(12)) and AUC(0-12) were significantly lower during the third trimester compared to postpartum (PAssuntos
Infecções por HIV/tratamento farmacológico
, Inibidores da Protease de HIV/farmacocinética
, HIV-1
, Nelfinavir/farmacocinética
, Complicações Infecciosas na Gravidez/tratamento farmacológico
, Adolescente
, Adulto
, Área Sob a Curva
, Contagem de Linfócito CD4
, Esquema de Medicação
, Feminino
, Infecções por HIV/metabolismo
, Inibidores da Protease de HIV/administração & dosagem
, Humanos
, Recém-Nascido
, Nelfinavir/administração & dosagem
, Gravidez
, Complicações Infecciosas na Gravidez/metabolismo
, Infecção Puerperal/tratamento farmacológico
, Infecção Puerperal/metabolismo
, RNA Viral
, Carga Viral
, Adulto Jovem